The Effectiveness of Nivolumab (OPDIVO®) Monotherapy as First-Line Therapy in Adults With Advanced (Unresectable or Metastatic) Melanoma: An Early Retrospective, Observational Study in Germany
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 11 Apr 2018 Planned initiation date changed from 1 Nov 2017 to 5 Jan 2018.
- 09 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Sep 2017 Planned End Date changed from 15 Dec 2017 to 31 Jan 2018.